Recent highlight publications of the last 5 years
1. Van Osch TLJ, Oosterhoff JJ, Bentlage AEH, Nouta J, Koeleman CAM, Geerdes DM, Mok JY, Heidt S, Mulder A, Van Esch WJE, Kapur R, Porcelijn L, Van der Schoot CE, De Haas M, Wuhrer M, Voorberg J, Vidarsson G. Fc galactosylation of anti-platelet hIgG1 alloantibodies enhance complement activation on platelets.
Haematologica. 2022 Mar 31. doi: 10.3324/haematol.2021.280493. In press
2. Hviid L, Lopez-Perez M, Larsen MD, Vidarsson G. No sweet deal: the antibody-mediated immune response to malaria.
Trends Parasitol. 2022 Mar 9:S1471-4922(22)00038-1. doi: 10.1016/j.pt.2022.02.008.
3. Brinkhaus M, van der Kooi EJ, Bentlage AEH, Ooijevaar-de Heer P, Derksen NIL, Rispens T, Vidarsson G. Human IgE does not bind to human FcRn.
Sci Rep. 2022 Jan 7;12(1):62. doi: 10.1038/s41598-021-03852-1. 2
4. Wojcik I, Schmidt DE, de Neef LA, Rab MAE, Meek B, de Weerdt O, Wuhrer M, van der Schoot CE, Zwaginga JJ, de Haas M, Falck D, Vidarsson G. A functional spleen contributes to afucosylated IgG in humans.
Sci Rep. 2021;11(1):24045. doi: 10.1038/s41598-021-03196-w
5. Larsen MD, Lopez-Perez M, Dickson EK, Ampomah P, Ndam NT, Nouta J, Koeleman CAM, Hipgrave Ederveen AL, Mordmüller B, Salanti A, Nielsen MA, Massougbodji A, van der Schoot CE, Ofori MF, Wuhrer M, Hviid L & Vidarsson G: Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination.
Nature Communications 2021; 12:5838. DOI 10.1038/s41467-021-26118-w
6. Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, Vidarsson G. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.
J Neurol Sci. 2021;430:118074. doi: 10.1016/j.jns.2021.118074.
7. van Osch TLJ, Nouta J, Derksen NIL, van Mierlo G, van der Schoot CE, Wuhrer M, Rispens T, Vidarsson G. Fc Galactosylation Promotes Hexamerization of Human IgG1, Leading to Enhanced Classical Complement Activation.
J Immunol. 2021;207(6):1545-1554. doi: 10.4049/jimmunol.2100399.
8. Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, van Dam KPJ, Stalman EW, Vogelzang EH, Cristianawati O, Keijzer S, Vidarsson G, Voskuyl AE, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
Lancet Rheumatol. 2021. doi: 10.1016/S2665-9913(21)00222-8.
9. Bye AP, Hoepel W, Mitchell JL, Jégouic SM, Loureiro S, Sage T, Vidarsson G, Nouta J, Wuhrer M, de Taeye SW, van Gils M, Kriek N, Cooper N, Jones I, den Dunnen J, Gibbins JM. Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets.
Blood. 2021;238(16):1481-9 doi: 10.1182/blood.2021011871.
10. Zwarthoff SA, Widmer K, Kuipers A, Strasser J, Ruyken M, Aerts PC, de Haas CJC, Ugurlar D, den Boer MA, Vidarsson G, van Strijp JAG, Gros P, Parren PWHI, van Kessel KPM, Preiner J, Beurskens FJ, Schuurman J, Ricklin D, Rooijakkers SHM. C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.
Proc Natl Acad Sci U S A. 2021;118(26):e2102787118. doi: 10.1073/pnas.2102787118
11. Braster R, Bögels M, Benonisson H, Wuhrer M, Plomp R, Bentlage AEH, Korthouwer R, Visser R, Verbeek JS, van Egmond M, Vidarsson G. Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice.
Cancers (Basel). 2021 May 14;13(10):2372. doi: 10.3390/cancers13102372.
12. Hoepel W, Chen HJ, Geyer CE, Allahverdiyeva S, Manz XD, de Taeye SW, Aman J, Mes L, Steenhuis M, Griffith GR, Bonta PI, Brouwer PJM, Caniels TG, van der Straten K, Golebski K, Jonkers RE, Larsen MD, Linty F, Nouta J, van Roomen CPAA, van Baarle FEHP, van Drunen CM, Wolbink G, Vlaar APJ, de Bree GJ, Sanders RW, Willemsen L, Neele AE, van de Beek D, Rispens T, Wuhrer M, Bogaard HJ, van Gils MJ, Vidarsson G, de Winther M, den Dunnen J. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages.
Sci Transl Med. 2021; 13(596):eabf8654. doi: 10.1126/scitranslmed.abf8654.
13. Temming AR, Tammes Buirs M, Bentlage AEH, Treffers LW, Feringa H, de Taeye SW, Kuijpers TW, Nagelkerke SQ, Brasser G, Mok JY, van Esch WJE, van den Berg TK, Rispens T, van der Schoot CE, Vidarsson G. C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro.
Front Immunol. 2021;12:594773. doi: 10.3389/fimmu.2021.594773.
14. Heemskerk N, Gruijs M, Temming AR, Heineke MH, Gout DY, Hellingman T, Tuk CW, Winter PJ, Lissenberg-Thunnissen S, Bentlage AE, De Donatis M, Bögels M, Rösner T, Valerius T, Bakema JE, Vidarsson G, van Egmond M. Augmented antibody-based anti-cancer therapeutics boost neutrophil cytotoxicity.
J Clin Invest. 2021 Feb 9:134680. doi: 10.1172/JCI134680.
15. Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, Chen HJ, Linty F, Visser R, Brinkhaus M, Šuštic T, de Taeye SW, Bentlage AEH, Toivonen S, Koeleman CAM, Sainio S, Kootstra NA, Brouwer PJM, Geyer CE, Derksen NIL, Wolbink G, de Winther M, Sanders RW, van Gils MJ, de Bruin S, Vlaar APJ; Amsterdam UMC COVID-19 biobank study group, Rispens T, den Dunnen J, Zaaijer HL, Wuhrer M, Ellen van der Schoot C, Vidarsson G. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.
Science. 2021;371(6532):eabc8378. doi: 10.1126/science.abc8378.
16. Brinkhaus M, Douwes RGJ, Bentlage AEH, Temming AR, de Taeye SW, Tammes Buirs M, Gerritsen J, Mok JY, Brasser G, Ligthart PC, van Esch WJE, Verheesen P, de Haard H, Rispens T, Vidarsson G. Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function.
J Immunol. 2020;205(12):3456-3467. doi: 10.4049/jimmunol.2000961.
17. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G, Bentlage AEH, van Haaren MM, Guerra D, Burger JA, Schermer EE, Verheul KD, van der Velde N, van der Kooi A, van Schooten J, van Breemen MJ, Bijl TPL, Sliepen K, Aartse A, Derking R, Bontjer I, Kootstra NA, Wiersinga WJ, Vidarsson G, Haagmans BL, Ward AB, de Bree GJ, Sanders RW, van Gils MJ:Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
Science. 2020;369(6504):643-650. doi: 10.1126/science.abc5902.
18. de Taeye SW, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D, Sénard T, Salehi N, Wuhrer M, Schuurman J, Labrijn AF, Rispens T, Vidarsson G: FcγR Binding and ADCC Activity of Human IgG Allotypes.
Front Immunol. 2020 May 6;11:740. doi: 10.3389/fimmu.2020.00740. eCollection 2020.
19. Temming AR, de Taeye SW, de Graaf EL, de Neef LA, Dekkers G, Bruggeman CW, Koers J, Ligthart P, Nagelkerke SQ, Zimring JC, Kuijpers TW, Wuhrer M, Rispens T, Vidarsson G. Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Journal of Immunology 2019;203(12):3126-3135. doi: 10.4049/jimmunol.1900985.
20. Temming AR, Dekkers G, van de Bovenkamp FS, Plomp HR, Bentlage AEH, Szittner Z, Derksen NIL, Wuhrer M, Rispens T, Vidarsson G: Human DC-SIGN and CD23 do not interact with human IgG.
Scientific Reports 2019;9(1):9995. doi: 10.1038/s41598-019-46484-2.
21. De Taeye SW, Rispens T, Vidarsson G: The Ligands for Human IgG and Their Effector Functions.
Antibodies 2019, 8(2), 30. Doi: 10.3390/antib8020030
22. van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA, van der Schoot CE, IJspeert H, van der Burg M, Gils A, Hafkenscheid L, Toes REM, Rombouts Y, Plomp R, Wuhrer M, van Ham SM, Vidarsson G and Rispens T. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region
PNAS 2018;115(8):1901-1906
23. Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Matlung H, van den Berg TK, van Esch WJE, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.
Frontiers in Immunology. 2017;8:877
24. Stegmann TC, Veldhuisen B, Nagelkerke SQ, Winkelhorst D, Schonewille H, Verduin EP, Kuijpers TW, de Haas M, Vidarsson G, van der Schoot CE. RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance.
Blood 2017;129(8):1045-1048.